CRIS Current Research Information System

GRANITO, ALESSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.649
AS - Asia 11.976
EU - Europa 8.080
AF - Africa 706
SA - Sud America 600
OC - Oceania 27
Continente sconosciuto - Info sul continente non disponibili 2
Totale 34.040
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.427
VN - Vietnam 3.693
CN - Cina 2.940
SG - Singapore 2.850
IT - Italia 1.953
GB - Regno Unito 1.450
DE - Germania 1.111
SE - Svezia 910
HK - Hong Kong 735
IN - India 478
FR - Francia 451
BR - Brasile 382
RU - Federazione Russa 354
IE - Irlanda 308
UA - Ucraina 284
NL - Olanda 283
KR - Corea 271
BD - Bangladesh 258
FI - Finlandia 240
JP - Giappone 213
TG - Togo 203
CH - Svizzera 172
ZA - Sudafrica 142
CA - Canada 116
CI - Costa d'Avorio 113
SC - Seychelles 102
EE - Estonia 96
AR - Argentina 94
AT - Austria 85
PH - Filippine 82
BG - Bulgaria 75
TH - Thailandia 66
MX - Messico 58
TR - Turchia 56
PL - Polonia 55
ID - Indonesia 52
IQ - Iraq 50
NG - Nigeria 46
BE - Belgio 45
JO - Giordania 43
PK - Pakistan 41
ES - Italia 38
TW - Taiwan 35
EC - Ecuador 30
GR - Grecia 23
MA - Marocco 23
CL - Cile 22
HR - Croazia 22
CO - Colombia 21
EG - Egitto 19
LT - Lituania 19
VE - Venezuela 19
SA - Arabia Saudita 18
UZ - Uzbekistan 18
AU - Australia 17
RO - Romania 17
CZ - Repubblica Ceca 13
IR - Iran 13
MY - Malesia 13
KE - Kenya 12
TN - Tunisia 12
DZ - Algeria 11
PE - Perù 11
PT - Portogallo 11
PY - Paraguay 10
AL - Albania 9
CR - Costa Rica 9
HU - Ungheria 9
JM - Giamaica 9
AZ - Azerbaigian 8
MK - Macedonia 8
NZ - Nuova Zelanda 7
RS - Serbia 7
UY - Uruguay 7
LV - Lettonia 6
NP - Nepal 6
SV - El Salvador 6
DK - Danimarca 5
LB - Libano 5
SK - Slovacchia (Repubblica Slovacca) 5
AO - Angola 4
DO - Repubblica Dominicana 4
GT - Guatemala 4
SY - Repubblica araba siriana 4
AE - Emirati Arabi Uniti 3
BH - Bahrain 3
BO - Bolivia 3
BY - Bielorussia 3
CY - Cipro 3
ET - Etiopia 3
HN - Honduras 3
IL - Israele 3
MD - Moldavia 3
NI - Nicaragua 3
NO - Norvegia 3
OM - Oman 3
PS - Palestinian Territory 3
SN - Senegal 3
BA - Bosnia-Erzegovina 2
CG - Congo 2
Totale 33.998
Salva come PNG Salva come JPEG
Città #
Singapore 1.921
Ashburn 1.350
Southend 1.233
Fairfield 1.021
Chandler 875
Ho Chi Minh City 775
San Jose 747
Dong Ket 688
Hanoi 677
Hong Kong 650
Hefei 542
Santa Clara 500
Woodbridge 490
Houston 456
Seattle 447
Wilmington 429
Bologna 394
Cambridge 346
Princeton 339
Beijing 329
Dublin 306
Boardman 295
Ann Arbor 261
Seoul 222
Council Bluffs 203
Lomé 203
Los Angeles 198
Helsinki 193
New York 186
Lauterbourg 182
Jacksonville 168
Tokyo 167
Milan 166
Munich 156
Dallas 153
Bern 152
Da Nang 135
Berlin 122
Frankfurt am Main 122
Nanjing 122
Haiphong 119
Westminster 119
Abidjan 113
Padova 109
Buffalo 107
Rome 103
Guangzhou 89
Jinan 78
Shenyang 77
Redondo Beach 73
Sofia 71
Turin 69
San Diego 65
São Paulo 65
Saint Petersburg 59
Vienna 58
Bremen 57
Changsha 57
Des Moines 57
Shanghai 56
Chicago 55
Phoenix 52
Bengaluru 51
Orem 45
Abeokuta 43
Hải Dương 43
Amman 42
Nanchang 42
Tianjin 41
Warsaw 39
Brussels 38
Mülheim 38
Falkenstein 37
Hebei 37
Atlanta 36
London 36
Nuremberg 35
Amsterdam 34
Florence 34
Redmond 34
Washington 33
Johannesburg 32
Hangzhou 31
Medford 30
Can Tho 29
Toronto 27
Zhengzhou 27
Montreal 26
Ningbo 26
San Francisco 26
Biên Hòa 25
Chengdu 25
Jakarta 25
Naples 25
The Dalles 25
Yubileyny 25
Olalla 24
Bến Tre 23
Wuhan 23
Bangkok 22
Totale 20.863
Salva come PNG Salva come JPEG
Nome #
Easy recognition and high autoimmune hepatitis specificity of smooth muscle antibodies giving an actin microfilament immunofluorescent pattern on embryonal vascular smooth muscle cells 551
Paraneoplastic Anti-Tif1-gamma Autoantibody-positive Dermatomyositis as Clinical Presentation of Hepatocellular Carcinoma Recurrence 382
Hepatic Steatosis in Patients with Celiac Disease: The Role of Packaged Gluten-Free Foods 318
Anti-Saccharomyces cerevisiae and perinuclear anti-neutrophil antibodies in coeliac disease before and after gluten free diet. 305
Monofocal hepatocellular carcinoma: How much does size matter? 298
COVID-19 and Immunological Dysregulation: Can Autoantibodies be Useful? 281
A multifaceted imbalance of T cells with regulatory function characterizes type 1 autoimmune hepatitis 280
Imaging-based diagnosis of benign lesions and pseudolesions in the cirrhotic liver 271
Bone Metastases from Intrahepatic Cholangiocarcinoma Confer Worse Prognosis 270
Clinical Impact and Safety of Anticoagulants for Portal Vein Thrombosis in Cirrhosis 261
Beneficial prognostic effects of aspirin in patients receiving sorafenib for hepatocellular carcinoma: A tale of multiple confounders 259
Antibodies to SS-A/Ro-52kD and centromere in autoimmune liver disease: a clue to diagnosis and prognosis of primary biliary cirrhosis. 258
Antinuclear antibodies in COVID 19 250
Clinical and serological profile of primary biliary cirrhosis in men. 249
A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma 244
Pattern of macrovascular invasion in hepatocellular carcinoma 244
Anti-ganglioside antibodies in coeliac disease with neurological disorders. 242
Antinuclear antibodies as ancillary markers in primary biliary cirrhosis. 242
Platelet count does not predict bleeding in cirrhotic patients: Results from the PRO-LIVER Study 242
'True' antimitochondrial antibody-negative primary biliary cirrhosis, low sensitivity of the routine assays, or both? 240
Landscape of alcohol-related hepatocellular carcinoma in the last 15 years highlights the need to expand surveillance programs 239
Anti-nuclear antibodies giving the “multiple nuclear dots” (MND) or the “rim-like/membranous” (RL/M) patterns: diagnostic accuracy for primary biliary cirrhosis. 238
Recalibrating survival prediction among patients receiving trans‐arterial chemoembolization for hepatocellular carcinoma 237
Clinical features of type 1 autoimmune hepatitis in elderly Italian patients 236
Characterization of primary and recurrent nodules in liver cirrhosis using contrast-enhanced ultrasound: which vascular criteria should be adopted? 236
Clinical impact of non-organ-specific autoantibodies on the response to combined antiviral treatment in patients with hepatitis C 233
Prognostic Impact of Metastatic Site in Patients Receiving First-Line Sorafenib Therapy for Advanced Hepatocellular Carcinoma 228
The duration of the conventional chemoembolization for hepatocellular carcinoma: factors affecting the procedural time 227
A COMPLEX IMMUNOREGULATORY DEFICIENCY CHARACTERISES TYPE 1 AUTOIMMUNE HEPATITIS. 227
Autoimmune enteropathy and rheumatoid arthritis: A new association in the field of autoimmunity. 221
Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon 219
Anti-actin IgA antibodies in severe coeliac disease 218
Role of Etiology in Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Counterfactual Event-Based Mediation Analysis 215
Current guidelines for the management of celiac disease: A systematic review with comparative analysis 213
The changing scenario of hepatocellular carcinoma in Italy: an update 211
Multiple nuclear dots and rim-like/membranous IgG isotypes in primary biliary cirrhosis. 211
Correlation between LDH levels and response to sorafenib in HCC patients: an analysis of the ITA.LI.CA. database 209
Impact of Sarcopenia on the Survival of Patients with Hepatocellular Carcinoma Treated with Sorafenib 207
Celiac disease diagnosed through screening programs in at-risk adults is not associated with worse adherence to the gluten-free diet and might protect from osteopenia/osteoporosis 207
Acute icteric hepatitis induced by a short course of low-dose cyclophosphamide in a patient with lupus nephritis 205
Clinical and economical impact of 2010 AASLD guidelines for the diagnosis of hepatocellular carcinoma 204
Material deprivation affects the management and clinical outcome of hepatocellular carcinoma in a high-resource environment 204
Metabolic disorders across hepatocellular carcinoma in Italy 201
A case of leptospirosis simulating colon cancer with liver metastases 200
Clinical Impact and behaviour of serum autoantibodies in adult liver transplantation 200
Impact of gadoxetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance on the non-invasive diagnosis of small hepatocellular carcinoma: a prospective study 199
Portal vein thrombosis relevance on liver cirrhosis: Italian Venous Thrombotic Events Registry 199
Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma 198
Suboptimal outcomes of sorafenib as a second-line treatment after atezolizumab-bevacizumab for unresectable hepatocellular carcinoma 195
CLINICAL FEATURES OF PRIMARY BILIARY CIRRHOSIS IN YOUNG AND ELDERLY PATIENTS. 194
Diagnosis and therapy of autoimmune hepatitis. 191
Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation. 189
Repeated Previous Transarterial Treatments Negatively Affect Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib 187
Anti-saccharomyces cerevisiae antibodies (ASCA) in coeliac disease. 186
Autoimmune liver disease 2007. 186
Cholangiocarcinoma in Cirrhosis: Value of Hepatocyte Specific Magnetic Resonance Imaging 185
Antibodies to filamentous actin (F-actin) in type 1 autoimmune hepatitis. 184
PML nuclear body component Sp140 is a novel autoantigen in primary biliary cirrhosis. 180
Autoimmune hepatitis in Italy: the Bologna experience. 180
Incidence and Recurrence of Portal Vein Thrombosis in Cirrhotic Patients 179
Clinical outcomes with long-term sorafenib treatment of patients with hepatocellular carcinoma: A multicenter real-life study 178
COVID-19: Has the Liver Been Spared? 178
Segmental Distribution of Hepatocellular Carcinoma in Cirrhotic Livers 177
Sensorineural hearing loss and celiac disease: a coincidental finding 177
The ART Score Is Not Effective to Select Patients for Transarterial Chemoembolization Retreatment in an Italian Series. 177
Antimitochondrial antibodies and other antibodies in primary biliary cirrhosis: diagnostic and prognostic value 177
New hallmark of hepatocellular carcinoma, early hepatocellular carcinoma and high-grade dysplastic nodules on Gd-EOB-DTPA MRI in patients with cirrhosis: A new diagnostic algorithm 177
Comparison of Prognostic Scores in Patients With Hepatocellular Carcinoma Treated With Sorafenib 177
Antitransglutaminase antibodies and giardiasis 176
Patterns of appearance and risk of misdiagnosis of intrahepatic cholangiocarcinoma in cirrhosis at contrast enhanced ultrasound. 176
Antibodies to gangliosides in coeliac disease with neurological manifestations. 175
The western immunoblotting pattern of anti-mitochondrial antibodies is independent of the clinical expression of primary biliary cirrhosis 175
Increased risk of nonalcoholic fatty liver disease in patients with coeliac disease on a gluten-free diet: beyond traditional metabolic factors 175
Clinical features and effect of antiviral therapy on anti-liver/kidney microsomal antibody type 1 positive chronic hepatitis C. 175
PO.8 COELIAC DISEASE MISDIAGNOSIS IN PATIENTS WITH COMMON VARIABLE IMMUNODEFICIENCY 175
Hepatocellular carcinoma in viral and autoimmune liver diseases: Role of CD4+ CD25+ Foxp3+ regulatory T cells in the immune microenvironment 173
Risk of Drop-Out from Follow-Up Evaluations for Celiac Disease: Is It Similar for All Patients? 172
Clinical and serological profile of primary biliary cirrhosis in young and elderly patients. 172
Specific antinuclear reactivities in primary biliary cirrhosis 170
Deamidated gliadin Peptide antibodies as a routine test for celiac disease: a prospective analysis. 170
PML NUCLEAR BODY COMPONENT SP140 IS A NOVEL AUTOANTIGEN IN PRIMARY BILIARY CIRRHOSIS. 169
Antifilamentous Actin Antibodies by ELISA for the Diagnosis of Type 1 Autoimmune Hepatitis. 169
DETECTION OF MND AND RL/M ANTI-NUCLEAR ANTIBODIES PATTERNS: A RELIABLE DIAGNOSTIC TOOL IN ANTI-MITOCHONDRIAL ANTIBODIES NEGATIVE PRIMARY BILIARY CIRRHOSIS. 166
null 164
Non-transplant therapies for patients with hepatocellular carcinoma and Child-Pugh-Turcotte class B cirrhosis 164
Immunoglobulin GM and KM allotypes and prevalence of anti-LKM1 autoantibodies in patients with hepatitis C virus infection. 163
Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients 163
Diagnostic accuracy of different patterns of contrast enhanced ultrasound in characterization of new nodules in liver cirrhosis with and without history of previous hepatocellular carcinoma. 162
INCREASED REGULATORY POTENTIAL AND IMBALANCE OF THE VDELTA1/VDELTA2 RATIO IN PATIENTS WITH DIFFERENT MANIFESTATIONS OF HEPATITIS C. 162
Celiac disease in autoimmune cholestatic liver disorders 162
Hierarchically Positioning Laparoscopic Microwave Ablation in the Therapeutic Span of Early Hepatocellular Carcinoma: A Real-Life Comparative Analysis 161
The serological profile of the autoimmune hepatitis/primary biliary cirrhosis overlap syndrome. 161
VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: The ALICE-1 study 160
TKIs in combination with immunotherapy for hepatocellular carcinoma 160
Evidence of a genetic basis for the different geographic occurrences of liver/kidney microsomal antibody type 1 in hepatitis C. 159
Systemic treatments for hepatocellular carcinoma: challenges and future perspectives 159
Outcome of hepatic resection for HCC in ideal and non-ideal candidates 158
Outcomes of Sorafenib for Recurrent Hepatocellular Carcinoma After Liver Transplantation in the Era of Combined and Sequential Treatments 157
Natural history of hypovascular hepatobiliary phase hypointense nodules on gadoxetic acid-enhanced mr imaging in cirrhotic patients during surveillance program 157
Sera of patients with celiac disease and neurologic disorders evoke a mitochondrial-dependent apoptosis in vitro. 154
Totale 20.697
Salva come PNG Salva come JPEG
Categoria #
all - tutte 98.575
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 98.575
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20223.341 237 60 204 251 259 169 81 237 131 263 927 522
2022/20233.827 411 503 188 492 255 315 198 182 615 132 274 262
2023/20241.307 76 182 95 116 115 245 70 126 59 72 89 62
2024/20254.983 223 556 554 354 693 301 466 200 121 362 264 889
2025/202613.144 990 1.125 1.009 840 1.226 624 1.771 416 2.748 1.009 609 777
2026/2027695 695 0 0 0 0 0 0 0 0 0 0 0
Totale 34.633